(FDA) increased the warning labels on over-the-counter NSAIDs to highlight elevated risks for
heart attack and stroke.
Increasing prevalence of respiratory diseases is expected to drive growth of the respiratory
tract infection treatment market
Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung
disease, pulmonary hypertension, and occupational lung disease are the major factors augmenting
growth of the respiratory tract infection market.
For instance, according to the Biomed Central Respiratory Research 2016, asthma and chronic
obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders
characterized by variable airflow limitation and airway hyper responsiveness, affecting over 25
million people in the U.S.
For More Information @
https://www.coherentmarketinsights.com/market-insight/respiratory-tract-infection-
treatment-market-2030
Various organizations, institutions, and agencies are working towards improving the diagnosis and
medical care needed to reduce the global burden of respiratory diseases. For instance, the Global
Alliance against Chronic Respiratory Diseases (GARD) was formed with the support from the
World Health Organization (WHO) to control chronic respiratory diseases. The main objective of
GARD is to develop simple and affordable strategies for chronic respiratory diseases (CRD) and to
encourage economies to implement health promotion and CRD prevention policies.
Presence of various drugs in pipeline, which is expected to be launched over the forecast period will
also boost the market growth of respiratory tract infection treatment. Some of the drugs in the
pipeline include Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead), AZD7594, and
PT010 (AstraZeneca).
However, presence of various generic manufacturers and low cost of various drugs including
antibiotics in the market may hinder the respiratory tract infection treatment market to some extent
during the forecast period.
Respiratory Tract Infection Treatment Market- Regional Analysis
On the basis of region, the global respiratory tract infection treatment market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold a dominant position in the global respiratory tract infection
treatment market over the forecast period, owing to increasing number of hospitalizations and
emergency visits associated with acute or life threatening medical problems.
According to the study by Society of Critical Care Medicine 2016, over 5.7 million patients are
admitted annually in intensive care units (ICUs) in the U.S. for support of airway, breathing or
circulation, and comprehensive management of injury.
Global Key Players:
Key players operating in the global respiratory tract infection treatment market include Abbott
Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical
Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd,
Sanofi, and Teva Pharmaceutical Industries Ltd.
Detailed Segmentation: